High plasma tumor necrosis factor (TNF)-alpha concentrations and a sepsis-like syndrome in patients undergoing hyperthermic isolated limb perfusion with recombinant TNF-alpha, interferon-gamma, and melphalan

Crit Care Med. 1996 May;24(5):765-70. doi: 10.1097/00003246-199605000-00007.

Abstract

Objectives: To describe the postoperative course of patients who underwent hyperthermic isolated limb perfusion with recombinant tumor necrosis factor (TNF)-alpha and melphalan after pretreatment with recombinant interferon-gamma as treatment for recurrent melanoma, primary nonresectable soft-tissue tumors, planocellular carcinoma, or metastatic carcinoma. To measure systemic TNF-alpha concentrations and relate these values with indices of disease severity.

Setting: A 12-bed surgical intensive care unit (ICU) in a university referral hospital.

Design: Prospective, descriptive study.

Patients: Consecutive patients (n=25) treated with hyperthermic isolated limb perfusion.

Interventions: Blood samples were taken at regular intervals to determine TNF-alpha concentrations during and after hyperthermic isolated limb perfusion with recombinant TNF-alpha. Hemodynamic variables were obtained with a Swan-Ganz pulmonary artery catheter.

Measurements and main results: All patients developed features of sepsis syndrome and required intensive care treatment. Most patients recovered quickly, with a median ICU stay of 2 days (range 1 to 25). Maximum systemic TNF-alpha concentrations ranged from 2284 to 83,000 ng/L (median 25,409) and returned to baseline values within 8 hrs. Despite these high concentrations of TNF-alpha, no patient died in the ICU, although the patient with the highest TNF-alpha concentration developed multiple organ failure and required continuous venovenous hemofiltration for 16 days. Linear regression analysis showed positive correlations between maximum TNF-alpha concentrations and systemic vascular resistance (p < .01), cardiac index (p < .02), Lung Injury Score (p < .02), prothrombin time (p < .02), and activated partial thromboplastin time (p < .05).

Conclusions: Hyperthermic isolated limb perfusion with recombinant TNF-alpha leads to high systemic concentrations of TNF-alpha, probably due to leakage of recombinant TNF-alpha from the perfusion circuit, mainly through collateral blood flow. A sepsis-like syndrome is seen in all patients. Despite high concentrations of systemic TNF-alpha, this sepsis syndrome is short-lived and recovery is rapid and complete in most patients.

Publication types

  • Clinical Trial

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Antineoplastic Agents, Alkylating / adverse effects*
  • Chemotherapy, Cancer, Regional Perfusion / adverse effects*
  • Combined Modality Therapy
  • Extremities
  • Female
  • Hemodynamics / drug effects
  • Humans
  • Hyperthermia, Induced / adverse effects*
  • Interferon-gamma / adverse effects*
  • Linear Models
  • Male
  • Melphalan / adverse effects*
  • Middle Aged
  • Neoplasms / therapy*
  • Prospective Studies
  • Recombinant Proteins
  • Severity of Illness Index
  • Systemic Inflammatory Response Syndrome / blood
  • Systemic Inflammatory Response Syndrome / chemically induced*
  • Tumor Necrosis Factor-alpha / adverse effects*
  • Tumor Necrosis Factor-alpha / metabolism*

Substances

  • Antineoplastic Agents, Alkylating
  • Recombinant Proteins
  • Tumor Necrosis Factor-alpha
  • Interferon-gamma
  • Melphalan